Atopic dermatitis (AD) is a chronic inflammatory skin disease that can significantly decrease quality of life. AD is commonly associated with comorbidities including ocular surface disease (OSD). Conjunctivitis is the most common OSD associated with AD and can increase in incidence with use of monoclonal antibody biologics that target the type 2 inflammatory pathway. The objective of this review is to raise awareness of comorbid OSD in AD patients that dermatologists may encounter, with a focus on conjunctivitis, and equip dermatologists to address mild ocular concerns. We provide background on the subtypes and pathogenesis of comorbid OSD in AD patients and describe OSD associated with type 2 inflammation-inhibiting AD biologics. We also discuss screening and diagnosis, recommended treatment options for dermatologists, and when to refer to an eye care specialist. This multispecialty approach aims to support the overall health of AD patients and provide optimal patient care., Competing Interests: Conflicts of interest Dr Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF); an advisor for the National Eczema Association; is a stock shareholder of Learn Health; and has served as an advisory board member, investigator, speaker, and/or received research funding from AbbVie, Altus Lab/cQuell, Aristea Therapeutics, Boehringer Ingelheim, Burt's Bees, Dermira, Ely Lilly, Galderma, GPSkin, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, MYOR, Novartis, Pfizer, Polyfins Techology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, SUN Pharma, Target-PharmaSolutions, and UCB. Dr Chamberlain is a medical advisor and/or investigator for Aslan Pharmaceuticals, Beyeonics, Cambium, Kowa, LEO Pharma, Noveome, Oyster Point, Regeneron, and Trefoil Therapeutics. Dr Siegfried receives contracted research fees, consulting fees, honoraria, and/or is an investigator for AbbVie, AI Therapeutics, ASLAN Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Incyte, Janssen, LEO Pharma, Novan, Novartis, Pierre Fabre, Pfizer, Regeneron, Sanofi Genzyme, UCB, and Verrica; and is a member of the Research Advisory Committee of the National Eczema Association. Dr Cooper has served as an advisory board member for LEO Pharma and as a speaker for Pfizer. Dr Beckman reports research grants/funding from Aerie, Alcon, Allergan, Avellino, Bausch & Lomb, BioTissue, Bruder, Dompe, Eyepoint, Eyevance, Glaukos, Glint, Johnson & Johnson, Kala, LEO Pharma, Novartis, Ocular Science, Ocular Therapeutix, Sun, TearLab, Visus, and Zeiss. Dr Lio reports research grants/funding from AbbVie, AOBiome, and Regeneron/Sanofi Genzyme; is on the speaker's bureau for Eli Lilly, Galderma, Incyte, LEO Pharma, L'Oreal, Pfizer, and Regeneron/Sanofi Genzyme; and reports consulting/advisory boards for AbbVie, Almirall, Altus Labs (stock options), Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, LEO Pharma, L'Oreal, Menlo Therapeutics, Micreos (stock options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, and Unilever. In addition, Dr Lio has a patent pending for a Theraplex product with royalties paid, and is a Board member and Scientific Advisory Committee Member of the National Eczema Association. Dr Paller is an investigator (contract to institution) for AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, KrystalBio, Regeneron, and UCB; consultant with honorarium for Abbvie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingeheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Kamari, LEO Pharma, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Regeneron, Sanofi/Genzyme, Seanergy, Trifecta, and UCB; and is on the Data Safety Monitoring Board for AbbVie, Bausch, Galderma, and Novan. Dr Simpson reports grants and/or personal fees from AbbVie, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, FortéBio, Galderma, Incyte, Kyowa Kirin, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, Novartis, Ortho Dermatologics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron, Sanofi, Tioga, and Valeant., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)